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Abstract 
Osteonecrosis of the jaw (ONJ), a potentially severe adverse effect of various medications (bisphosphonates, 
antiresorptive and antiangiogenic drugs). has unclear pathogenesis although some risk factors have been recognized. 
This observational study will describe a multicenter, case series of patients affected with RA (a potential risk factor) and 
ONJ, and it will attempt to evaluate the association between features of ONJ and pharmacological, systemic and site 
variables. 
Demographic, pharmacological and clinical data from 18 RA patients with ONJ were collected and registered from 
three Italian centres (i.e. Palermo, Verona, Padua) from 2004 to 2013. 
Sixteen(88.9%) patients were in therapy for RA:  9/18 (50.0%) with systemic steroids, 3/18 (16.7%) with methotrexate, 
and 4/16(22.2%) with both drugs. Two patients were not receiving treatment for RA. All patients took NBPs for 
secondary osteoporosis (average duration of 69 months, range 20-130): fifteen (83.3%) patients were treated with single 
NBPs, while 3/18(16.7%) with different molecules; one patient was also treated with denosumab. Mandible was 
affected more frequently (66.7%) than maxilla (33.3%); one patient presented multiple ONJ events. 
This is the first multicenter case series in the international literature. It could be hypothesized that RA patients may be 
more susceptible to ONJ than the majority of osteometabolic patients. 
 
Keywords. Rheumatoid Arthritis, Osteoporosis, Bisphosphonate, Denosumab, Jaw, Osteonecrosis, ONJ. 
 
INTRODUCTION 
Rheumatoid Arthritis (RA) is a systemic, inflammatory, autoimmune disorder, characterized by progressive joint 
destruction and various systemic manifestations (e.g. hematological, neurological, respiratory, and cardiovascular 
events). RA is more frequent in women with a prevalence of about 1%, thereby suggesting a role for sex hormones. The 
annual incidence rate of RA varies between 20 and 50 cases per 100,000 in North American and north European 
countries, and it may be lower in south European countries (Alamanos et al., 2006, Carbonell et al., 2008); 
unfortunately, incidence studies from other countries are not currently available. RA is the most common form of 
inflammatory arthritis with the highest propensity to overstep in cases of synovitis, infiltrating articular bone and 
cartilage. Three types of alterations in bone mass can be recognized in RA patients: periarticular bone loss, joint 
erosions and generalized bone loss. Key drugs in the therapeutic regimens of RA are glucocorticoids (GCs), which have 
demonstrated a slowing of radiographic progression(Jacobs et al., 2014).  Furthermore, the prescribing of Disease 
Modifying Anti-Rheumatic Drugs (DMARDs), such as metotrexate (MTX), is another essential regimen for RA therapy 
and is widely used(Dimitroulas et al., 2013). The event of generalized bone loss is a secondary osteoporotic condition, 
and it can be frequently aggravated by: (a) therapy with GCs and/or MTX (Salute), commonly used to treat RA; (b) 
physical inactivity (Vasquez et al., 2013), typically due to RA pain; and (c) inflammatory disease mechanisms (e.g. 
elevated levels of systemic cytokines) (Bartold et al., 2005). In particular, the osteoclast pathway is galvanized by an 
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alteration in immune status, accompanied by chronic inflammation; the latter is a typical condition in periarticular 
osteoporosis and local bone destruction around the joints (Ono et al., 2013). It has been reported that, in an observed 
population, 94.6 % of the patients were given a therapy of DMARDs; 82.5 % of the patients receiving methotrexate 
additionally received folic acid; and 65.9 % of the patients received calcium and vitamin D(Hartmann et al., 2008) and 
glucocorticoids. In order to prevent or treat primary or secondary osteoporosis, RA patients take bisphosphonates (BPs): 
prescription of nitrogen-containing bisphosphonate (NBP) or non nitrogen-containing bisphosphonate (NBP) are 
frequently used. Alendronate has been the most prescribed oral NBP formulation (Piscitelli et al., 2014) and, to date, it 
has been frequently related to the severe BP-related adverse drug reaction named as osteonecrosis of the jaw BRONJ 
(bisphosphonate-related ONJ) (Di Fede et al., 2013). Firstly, BRONJ was observed by Marx and Stern in 2002. 
Extensive case series regarding BRONJ were published in 2003 by Marx and in 2004 by Ruggiero et al (Marx, 2003, 
Ruggiero et al., 2006); currently, an increasing number of publications relating to BRONJ is available in the literature. 
Recently, BRONJ was defined by Bedogni et al. as a ”progressive destruction and death of bone that affects the 
mandible and/or maxilla of patients, exposed to treatment particularly with NBPs, in the absence of a previous radiation 
treatment (Bedogni et al., 2012)”. In subjects exposed to NBPs, following a localized  trauma, such as tooth extraction, 
the jaw could generally fail to heal, leaving the bone exposed in many cases (Capsoni et al., 2006).  There are, however, 
numerous reports describing ONJ with symptoms and/or minor signs but in the absence of bone exposure (Fedele et al., 
2010, Mawardi et al., 2009, Bedogni et al., 2014). Bone lesions can be observed more frequently in the mandible and 
less in the maxilla(Vescovi et al., 2012, Otto et al., 2012, Khan et al., 2015); both mandible and maxilla have been 
found in different percentages (5-11.1%)(Otto et al., 2012, Gammelager et al., 2013). Furthermore, other 
antiangiogenics (e.g. bevacizumab) and/or antiresoptive (e.g. denosumab, sunitinib) drugs have been associated with  
ONJ (Cardona Tortajada et al., 2014, Fedele et al., 2015, Fangusaro et al., 2013, Fusco et al., 2014). 
The epidemiology of ONJ remains unclear due to the inconsistency and limitations of available studies.  These include: 
a lack of a specific ICD code; under-reporting in Surveillance Drug Systems; a recent introduction of preventive 
measures; case adjudication restricted to exposed ONJ; short-term observation; and a lack of cumulative long-term 
incidence rates(Campisi et al., 2014). Very recently, English authors have estimated that the incidence of ONJ in the 
oncological and osteometabolic population is approximately 10 cases/million/year(Rogers et al., 2014). A wide-ranging 
incidence of ONJ from 0% to 27.5% has been reported for individuals exposed to intravenous BP(Kuhl et al., 2012). In 
patients receiving oral NBPs, ONJ data should be treated with caution. (Reid, 2009). Generally, a prevalence of ONJ 
ranging from 0.001% to 0.4% (Conte-Neto et al., 2012, Malden & Lopes, 2012, Lo et al., 2010, Landesberg & Taxel, 
2013) has been reported in RA patients. Whilst the pathogenesis of ONJ is unclear, various risk factors are not well 
recognized and they are usually categorized into three groups: drug-related, local, and demographic/systemic risk 
factors (2007, Ruggiero et al., 2006). Of the systemic risk factors, Rheumatoid Arthritis (RA) has been markedly 
considered (Park et al., 2010, Malden et al., 2009), although a comprehensive study has yet to be performed.  
 
Rationale 
The case reports of a few RA patients (Conte Neto et al., 2011, Conte-Neto et al., 2012, Conte-Neto et al., 2011, 
Manzon et al., 2014, Alsalleeh et al., 2014, Ebker et al., 2013, Junquera et al., 2009, O'Ryan & Lo, 2012, A. Fasciolo, 
2014, A. Nori, 2014) have been described in the literature.  In addition to discussing the prescription of NBPs for 
treating or preventing cases of osteopenia/osteoporosis, further factors leading to ONJ in RA patients have been 
hypothesized: chronic inflammatory alterations (Conte Neto et al., 2011); the immuno-suppressive action of 
corticosteroids (Coutinho & Chapman, 2011); and MTX (Herman et al., 2004) predisposing to local infections 
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(Fleischmann et al., 2006). In order to reduce any bias and to verify a possible link between RA and ONJ, multicentric 
studies are required.  
METHODS  
Study design  
A retrospective cohort study was reported according to the STROBE (Strengthening the Reporting of Observational 
Studies in Epidemiology) recommendations(von Elm et al., 2014). The Ethical Committees of the participating centres 
approved the study (N 4/2012 18-04-2012) and patient consent was obtained where specifically required. 
Setting 
Researchers at the Universities of Palermo, Verona and Padua designed the study and sent a collaboration proposal to 
their centres of Oral Medicine and/or Maxillofacial Surgery with a special interest in the diagnosis of ONJ in patients 
affected by RA.  
Participants 
Selection and eligibility criteria  
Patients, referred to the participating centres between January 2004 and December 2011, were eligible for our study if: 
1) they were affected by RA; 2) had previously had, or were currently having, treatment with bisphosphonates and/or 
denosumab; 3) they had exposed ONJ (defined as the presence of long-standing - > 8 weeks - transmucosal exposure of 
necrotic jawbone  (Ruggiero et al., 2009)) or non-exposed ONJ (defined as the presence of otherwise unexplained 
jawbone pain, fistula, swelling, mobile teeth or mandibular fracture, as defined by Fedele et al (Fedele et al., 2010)); 4) 
they had no history of head-neck radiotherapy; and 5) there existed CT scan imaging (spiral or cone-beam) of the 
affected jawbones. Only patients with CT scans performed within 6 months from clinical phenotyping were included, in 
order to have a concordance between clinical manifestations and CT findings. Dentascan reformatted images were not 
considered as they do not accurately display the ramus of the mandible and the midfacial bones. 
Criteria for exclusion were off-label use of BPs and the presence of associated tumor growth in  the jaws. ONJ case-
adjudication throughout all the centres was performed by multidisciplinary teams which included BP prescribers and 
specialists in Oral Medicine and/or in Maxillofacial Surgery.  Each report was supported by a qualitative case-by- case 
assessment procedure, which  was performed by an officially – recognized drug expert.  
Data collection and variables 
The hospital notes of consecutively diagnosed ONJ patients were retrospectively reviewed between June 2012 and 
September 2013. The following data (clinical, radiological measurement) relevant to the study were extracted by local 
clinical teams and entered into a pre-defined electronic case report form by one clinician at each institution. 
The following clinical measurements were collected from the clinical charts: 1) age; 2) sex; 3) underlying bone 
disorders and co-morbidities; 4) NBP type; 5) duration of NBP treatment; 6) NBP cumulative dose; 7) the simultaneous 
or select use of antiresorptives (e.g. denosumab); 8) the concurrent use of steroids and/or methotrexate; or 9) other 
drugs, such as antiangiogenic agents (i.e. sunitinib and bevacizumab); 10) the time period leading up to ONJ onset; 11) 
the presence of known risk factors for ONJ (tooth extraction, dental or periodontal infection, an ill-fitting prosthesis and 
dental implant surgery); 12) the ONJ site; 13) the presence of exposed bone; and  14) the presence of minor clinical 
signs and symptoms.  
Radiologic measurements were analyzed by panoramic radiograph and computed tomography (CT) 
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The staging of the disease was based on the current clinico-radiological staging system, as proposed by SICMF-
SIPMO(Bedogni A, 2013). 
Statistical analysis  
The two responses of the study were bone exposure, coded as negative or positive, and the ONJ stage, coded according 
to SICMF-SIPMO and dichotomized as stage 2 or 3 vs stage 1. [49]. To summarize demographical data and outcomes, 
categorical values were expressed as counts and percentages %. Quantitative variables, such as NBP cumulative dose 
(mg) and NBP duration (months), were expressed as the median value and the interquartile range (the 25th and 75th 
percentiles).  At univariate analysis, the association of both responses with pharmacological, systemic and clinical 
variables, and the association between either corticosteroid therapy or tooth extraction with NBP features were tested 
using the Fisher’s exact test. Furthermore, crude Odds Ratios (OR) and 95% Confidence Intervals (CI) were calculated 
as association measures. NBP duration and cumulative dose were dichotomized using the median value. Aledronate was 
chosen as a reference for the type of administered NBP. Multivariate analysis was not performed, in the absence of 
statistically significant variables at univariate analysis. A p value < 0.05 was chosen to represent statistical significance. 
Data were analysed using STATA SE, v. 14.1. 
 
RESULTS 
Details of the study population: Eighteen patients affected by RA and ONJ were considered eligible: 16 patients were 
females and 2 males, the median age was 69 years (interquartile range 63-72 years). Sixteen (88.9%) patients were in 
therapy for RA:  9/18 (50.0%) with systemic steroids, 3/18 (16.7%) with methotrexate, and 4/16 (22.2%) with steroid 
and methotrexate. Two RA patients declared that they were not currently receiving any treatment. All patients suffered 
from secondary osteoporosis and 11/18 (61.1%) showed further morbidities (e.g. diabetes, coagulopathy). All had been 
treated with bisphosphonates. More than half (11, equal to 61.0%) of the patients were treated with aledronate, and 
three of them also received another NBP. Four patients (22.2%) were treated with Ibadronate, 2 (11.1%) with 
Risedronate and 1( 5.6%) with Zoledronate. In the subgroup of patients who had only used Alendronate, the median 
cumulative dose was 15120 and the median duration of NBP therapy was 69 months. The mandible was affected by 
ONJ more frequently (66.7%) than the maxilla (33.3%), and one patient presented more than one localization of ONJ 
(mandible and maxilla). ONJ appeared as exposed in 11 (61.1%) patients and as the non-exposed variant in 7 (38.9%) 
subjects. Regarding the ONJ staging, according to Bedogni (Bedogni et al., 2012): 4 patients had stage 1 ONJ (22.2%), 
11 patients had stage 2 (61.1%) and 3 patients had stage 3 (16.7%). Tooth extraction (due to dental/periodontal 
diseases) was identified in 9 (50.0%) patients as a trigger ONJ event.  There was evidence of periodontal chronic 
disease in 5 (27.8%) subjects, prosthetic trauma in 1 (5.6%) case and  dental implant infection in 3 other cases (16.7%). 
Of note, implant surgery was carried out before NBP administration in all cases.  Other clinical and pharmacological 
records of the  sample are shown in Table 2. 
When bone exposure was associated with pharmacological, systemic, local and clinical variables, no significant 
association was found (Table 2). Neither treatment with corticosteroid therapy nor tooth extraction as an ONJ trigger 
event were significantly associated with NBP features (Table 3). 
 
DISCUSSION  
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Osteonecrosis of the jaw (ONJ) is a rare and serious adverse side event, particularly related to  the administration of 
NBPs. Its epidemiology and pathogenesis remain for the most part unclear although significant improvements have 
been made regarding its definition, diagnosis and staging, prevention strategies and treatment; additional risk factors 
have yet to be recognized.  
Generally, the effective risk of ONJ in patients treated with NBPs for osteometabolic diseases is not particularly well- 
known, in part due to the paucity of crucial information.  The latter include the exact total number of patients exposed to 
NBPs and the precise interplay of the elevated number of potential risk factors implicated. Even less is known about 
ONJ risk in RA patients. NBPs are the main drugs associated with ONJ but they are not the only ones. Indeed, 
denosumab, which has recently been used to treat secondary osteoporosis,  is also considered to be  ONJ-related. 
Systemic steroids and methotrexate MTX are generally prescribed, also in combination, to manage chronic diseases 
such as RA, a systemic autoimmune disease characterized by progressive joint destruction and a variety of systemic 
manifestations resulting from chronic inflammation. Although RA has been proposed as one of the risk factors of ONJ 
(Conte-Neto et al., 2011), no RCT has been published for establishing the effective  association between ONJ and RA, 
and fewer papers discussing epidemiological data have been produced.  
Several relevant factors linking RA and ONJ have been discussed(Conte Neto et al., 2011): the role of steroids and 
other immunosuppressive agents, such as MTX for the inhibition of bone remodeling;  NBP could increase the arthritic 
process, thereby increasing flogosis; the antiangiogenic activity of NBP determining the loss of blood vessels; 
inflammation by RA due to its deleterious effects on bone tissues directly or by mediators; concomitant diseases, such 
as periodontitis and osteomyelitis, which are common in RA patients; and NBP and/or MTX toxicity theory. NBPs 
exclusively affect the phagocytic cells and not other types of cells and the local immune response could also be 
compromised. Indeed, since bisphosphonates do not affect neutrophils, the risk of systemic infection is low. The 
reduced function of monocytes and macrophages could become critical for the development of ONJ (Pazianas, 2011). 
Some of aforementioned and controversial hypothesis have been recognized in our study: the majority of the ONJ 
patients (88.9%) were undergoing therapy with steroids and/or MTX to treat RA, and many local inflammatory features 
were recognized; on the other hand, in 5/18 (27%) who did not take GCs, other factors (such as MTX therapy or 
flogosis activation) could play a predominant role. Moreover, there were other two subjects who had never been in 
treatment for RA either with systemic corticosteroids or MTX and they presented even more advanced conditions of 
local flogosis than the RA patients undergoing therapy. The authors of these points consider them to be very important 
in taking them into account regarding an ONJ prognosis.  Indeed O'Ryan  and Lo (O'Ryan & Lo, 2012) have recently 
observed that ONJ patients taking oral BPs with relevant comorbidities, such as RA, had  a lower probability of healing 
and a longer median time in  healing than patients without comorbidities. 
Some years ago, an extended literature review (Conte-Neto et al., 2012) was conducted with the aim of evaluating  
important issues relating to RA patients who had developed ONJ, including demographic, clinical, and treatment 
aspects.  The goal of this study was to establish comparative associations between  patients without RA but who had 
developed oral BRONJ.  Different research was compared with different descriptive procedures and considered 
variables. The sample of data discussed in this Paper was collected in accordance with the same research protocol, 
applying and aggregating data  from different regions (a multicenter study). This, therefore, reduced the probability of 
missing data, thereby  producing a homogeneous sample. RA patients who developed ONJ lesions after an oral NBP 
intake were usually female, 60+ years old, as has already been observed by other researchers (Conte-Neto et al., 2011).  
In the patient group in this study, alendronate – an oral NBP – was found to be that most associated (61.1%) with 
osteonecrosis.  It is also the most prescribed drug for preventing and treating osteoporosis, as confirmed by Malden and 
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Lopes (Malden & Lopes, 2012). The duration of NBP in the RA patients with ONJ in this study varied from 1-130 
months, similar to that previously reported (2-120 months) (Di Fede et al., 2013) in the osteoporotic case series. 
Moreover, it is notable that the longer-term use of oral NBPs, as is usual for RA therapy, may have a dose equivalence 
effect, potentially approximating to that of BP levels in bone, which is thought to be achieved only through high-dose 
intravenous delivery.  
Of note, it is interesting to observe the absence of spontaneous ONJ in our sample, that is, when any systemic and/or 
local risk factors were not recognized: excluding the presence of RA, whose  hypothesis of ONJ onset was not defined, 
one or more ONJ risk factors were recognized in every patient. Thus, the presence of RA might lead to enhanced 
susceptibility, as previously speculated, even if evidence for this is currently lacking.   
In order to evaluate the site and characteristics of ONJ in the RA patients in this study, we observed that the mandible 
was most prevalently involved (61.1%) and this fact has been  published by other researchers in the field (Diniz-Freitas 
et al., 2012, Di Fede et al., 2013).  Furthermore, a high percentage of cases (38.9%) did not present bone exposure but 
they did display minor clinical and radiological signs, according to Bedogni et al (Bedogni et al., 2012).   
In conclusion and in light of the data presented in this Paper, it could be hypothesized that patients with RA, when 
exposed to NBP, may be more susceptible to ONJ than the majority of osteometabolic patients.  Evidently, one 
significant limitation of our research is the absence of RCTs dealing with this issue.  This surely points to the direction 
of future research. 
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Table 1- Demographical data and outcomes. 
 
§ 3 of 12 patients treated with Alendronate receive also another NBP 
AR + BRONJ analyzed  patients 
 
Median age (yrs) 
Interquartile range (yrs) 
Mean age±SD (yrs) 
18 
 
69 
63-72 
68.0±8. 
 
 n(%)  
Gender 
Female 
Male 
 
16 (88.9) 
2 (11.1) 
 
 YES NO 
Other comorbidities 11 (6.1) 
 
7 (38.9) 
AR therapy   
Corticosteroid therapy 13 (72.2)  5 (27.8) 
Methotrexate therapy 7 (38.9) 11 (61.1) 
   
Other drugs   
Denosumab therapy 1 (5.6) 17 (94.4) 
   
Type of administered NBP 
Alendronate§ 
Ibadronate 
Risedronate 
Zoledronate 
n(%) 
11 (61.) 
4(22.2) 
2(11.1) 
1(5.6) 
 
 
Mono NBP 
Poli NBPs 
 
15 (83.3) 
3(16.7) 
 
   
 
NBP duration (months) 
NBP cumulative dose (mg) 
 
Range 
20-130 
5-36400 
Median (Q1-Q3) 
69 (48-99) 
15120 (0-27720) 
BRONJ site  
Mandible 
Maxilla 
 
12(66.7) 
6(33.3) 
 
  
YES 
42.1 
Bone exposure  11 (61.1) 7 (38.9) 
 
BRONJ staging  (ref SICMF-SIPMO) 
Stage 1 
Stage 2 
Stage 3 
 
4 (22.2) 
11 (61.1) 
3 (16.7) 
 
   
Trigger event (Local risk factors for BRONJ) 
 
 
 
Tooth extraction 
Periodontal infection  
Prosthetic trauma 
Implant infection 
YES 
 
18(100.0) 
 
9 (50.0) 
5 (27.8) 
1  (5.6)  
3 (16.7) 
NO 
 
0(0.0) 
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Table 2 - Statistical significance of the univariate association between bone exposure and 
SICMF SIPMO staging with pharmacological, systemic and clinical variables. 
 
 Bone exposure SICMF SIPMO 
staging 
Type of administered 
NBP 
 
0.589 0.112 
NBP cumulative dose2 1.000 0.576 
NBP duration3 1.000 1.000 
Implant infection 1.000 1.000 
Periodontal infection 0.596 0.278 
Prosthetic trauma 
 
0.3891 1.000 
Tooth extraction 1.000 0.082 
Other comorbidities 1.000 1.000 
Corticosteroid therapy 0.326 1.000 
Methotrexate therapy 0.637 1.000 
Denosumab therapy 1.000 1.000 
BRONJ site 0.627 1.000 
1Fisher’s exact test p-value. p-values<0.05 were statistical significant 
2Cumulative dose >15120 vs <=15120 (Median value); 3Duration>69 vs <=69 (Median value) 
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Table 3 
 Steroids Tooth extraction 
Type of administered 
NBP 
 
1.000 0.506 
NBP cumulative dose2 1.000 1.000 
NBP duration3 1.000 1.000 
 
 
 
